The parental continuous cell line HELA was established from the primary cervix carinoma of a 31-year-old black woman 1951; KB-3-1 is a derivative of HELA and is used in multiple drug resistance studies giving raise to drug-resistant mutants (e.g. KB-V1 resistant to vinblastine; KB-CHR-8-5 resistant to colchicine); cells express MYC mRNA; the cell line will only be distributed to non-profit institutions, commercial entities may apply for a license at the NIH/NCI Technology Transfer Cernter, Rockville, MD, USA, phone (301)435-3111